ZetrOZ Systems Strengthens Its Commitment to Non-Invasive Healing
ZetrOZ Systems, the company behind Sustained Acoustic Medicine (SAM) and the sam wearable ultrasound device, has announced the expansion of its partnerships with leading medical foundations and national advocacy organizations. The goal is simple: help more patients learn about and access a proven treatment option for soft-tissue injuries.
As more people look for alternatives to surgery and pain medication, ZetrOZ Systems is working closely with healthcare organizations to improve awareness of its wearable ultrasound technology and support better patient outcomes.
What Is the SAM Wearable Ultrasound Device?
The sam wearable ultrasound device is an FDA-cleared technology designed for prescription home use. It is used to treat both acute and chronic soft-tissue injuries.
The device works by delivering high-frequency ultrasound energy directly to injured tissues over an extended period. This process helps:
Unlike many traditional treatment approaches, the SAM device allows patients to receive therapy from the comfort of their homes.
Clinical Evidence Supports the Technology
The growing interest in sustained acoustic medicine is backed by extensive scientific research.
According to ZetrOZ Systems, more than 40 peer-reviewed studies have shown that the SAM device can:
This body of evidence has helped position the technology as a practical treatment option for a variety of musculoskeletal conditions.
Partnership With the Osteoarthritis Action Alliance
One of ZetrOZ Systems' key partnerships is with the Osteoarthritis Action Alliance (OAAA).
The alliance is a national coalition supported by the Arthritis Foundation and the U.S. Centers for Disease Control and Prevention (CDC). Its mission is to improve awareness, prevention, and treatment of osteoarthritis.
Since the SAM device has demonstrated benefits in managing osteoarthritis symptoms, the partnership aligns closely with the alliance's objectives.
George K. Lewis, Founder and CEO of ZetrOZ Systems, explained that the company is proud to support efforts that improve outcomes for people living with osteoarthritis and help expand access to evidence-based treatment options.
Supporting Future Healthcare Professionals
ZetrOZ Systems is also investing in healthcare education through its sponsorship of the Orthopaedic Foundation's Manhattan Medical Immersion Camp.
This hands-on educational program is designed for high school and college students interested in careers in medicine, biomedical engineering, and healthcare research.
Participants gain practical experience through:
The program helps students better understand how innovative medical technologies are changing patient care and treatment approaches.
According to Lewis, introducing students to technologies like sustained acoustic medicine helps bridge the gap between classroom learning and real-world healthcare applications.
Advancing Sports Medicine Through Research
Another important collaboration involves the NATA Research & Education Foundation.
The foundation has supported athletic training research and education for decades and has awarded more than $10 million in grants and scholarships since 1991.
ZetrOZ Systems currently supports several foundation initiatives.
Free Communications Program
This program provides researchers and clinicians with a platform to share research findings, clinical experiences, and new treatment approaches.
Free Communications Awards
These awards encourage both professional and student athletic trainers to conduct research that advances sports medicine and athletic healthcare.
Research to Clinical Practice Newsletter
The newsletter helps connect athletic trainers with the latest evidence-based research and practical clinical applications.
Through these initiatives, ZetrOZ Systems is helping promote scientific advancement and improved patient care within the athletic training community.
A Growing Alternative to Surgery and Pain Medication
As healthcare providers continue searching for safer and more effective treatment options, the SAM device offers a different approach.
Rather than relying on invasive procedures or long-term medication use, patients can receive non-surgical and non-drug therapy that supports the body's natural healing processes.
The technology is currently used in millions of treatment sessions every year across the United States.
Its growing adoption reflects increasing interest in non-invasive solutions for managing soft-tissue injuries and chronic musculoskeletal conditions.
Making Recovery Easier for Patients
One of the major advantages of the SAM device is its convenience.
Because it is designed for home use, patients can continue their treatment without frequent clinic visits. This flexibility allows individuals to take a more active role in managing their recovery while maintaining their daily routines.
For many patients, this combination of convenience, comfort, and clinical effectiveness makes wearable ultrasound therapy an attractive treatment option.
Looking Ahead
ZetrOZ Systems continues to expand awareness of sustained acoustic medicine through strategic partnerships, educational programs, and research initiatives.
Backed by 48 U.S. and international patents and supported by more than 30 clinical trials, the company's technology is gaining recognition as an important tool in non-invasive injury treatment.
As the demand for effective, drug-free, and surgery-free treatment options continues to grow, ZetrOZ Systems is positioning itself to play an increasingly important role in the future of musculoskeletal care.
About ZetrOZ Systems
ZetrOZ Systems is the inventor of Sustained Acoustic Medicine and the SAM wearable ultrasound device. The company develops patented, FDA-cleared technologies designed to treat soft-tissue injuries through long-duration ultrasound therapy.
Its innovations are protected by 48 global patents and supported by extensive clinical research, helping provide patients and healthcare professionals with evidence-based alternatives for injury treatment and recovery.